Biohaven Pharma (BHVN)
11.75
-0.06 (0.51%)
Upcoming Events
Latest Headlines
Form 8-K Biohaven Ltd. For: Oct 08
October 15, 2026 5:19 PM - SEC Filing
Canaccord Reiterates Buy Rating on Biohaven Pharma (BHVN)
October 9, 2026 7:05 AM - StreetInsider
Citi reiterates Buy rating on Biohaven Pharma after licensing deal
October 8, 2026 9:52 AM - StreetInsider
Raymond James Reiterates Strong Buy Rating on Biohaven Pharma (BHVN)
October 8, 2026 9:50 AM - StreetInsider
Biohaven licenses IgG degrader portfolio to Ono for $100M
October 8, 2026 4:00 AM - StreetInsider
Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease
October 8, 2026 4:00 AM - PR NewsWire
Biohaven's BHV-1530 cancer drug selected for ENA 2026 presentation
September 28, 2026 7:31 AM - StreetInsider
Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026
September 28, 2026 7:30 AM - PR NewsWire
Citi reiterates buy rating on Biohaven Pharma amid rival's trial pause
September 18, 2026 5:17 AM - StreetInsider
Form 4 Biohaven Ltd. For: Sep 15 Filed by: Gentile Kimberly
September 17, 2026 6:15 PM - SEC Filing
H.C. Wainwright Reiterates Neutral Rating on Biohaven Pharma (BHVN)
September 11, 2026 6:59 AM - StreetInsider
Baird Reiterates Outperform Rating on Biohaven Pharma (BHVN), "no change to outlook"
September 10, 2026 10:14 AM - StreetInsider
Biohaven stock tumbles after pausing trial enrollment
September 10, 2026 7:26 AM - StreetInsider
Form 8-K Biohaven Ltd. For: Sep 04
September 10, 2026 6:03 AM - SEC Filing
RBC Capital Downgrades Biohaven Pharma (BHVN) to Sector Perform
September 8, 2026 2:19 AM - StreetInsider
Canaccord Reiterates Buy Rating on Biohaven Pharma (BHVN)
August 28, 2026 8:10 AM - StreetInsider
H.C. Wainwright Reiterates Neutral Rating on Biohaven Pharma (BHVN)
August 27, 2026 7:07 AM - StreetInsider
TD Cowen Reiterates Buy Rating on Biohaven Pharma (BHVN)
August 26, 2026 11:01 AM - StreetInsider
Biohaven Pharma (BHVN) PT Lowered to $30 at Raymond James
August 26, 2026 10:17 AM - StreetInsider
Biohaven licenses Kv7 epilepsy platform to SK Biopharma for up to $795M
August 26, 2026 7:05 AM - StreetInsider
Form 8-K Biohaven Ltd. For: Aug 26
August 26, 2026 6:39 AM - SEC Filing
Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy
August 26, 2026 2:37 AM - PR NewsWire
Court awards Biohaven and Yale $4M in trade secret case
August 25, 2026 4:44 PM - StreetInsider
Federal Court Enters Judgment Confirming RA Capital and Avilar Therapeutics Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Formalizing $4 Million Award to Biohaven and Yale
August 25, 2026 4:42 PM - PR NewsWire
Form 3 Biohaven Ltd. For: Aug 06 Filed by: Yetimoglu John
August 14, 2026 6:01 PM - SEC Filing
Form SCHEDULE 13G Biohaven Ltd. Filed by: Woodline Partners LP
August 14, 2026 11:01 AM - SEC Filing
Biohaven Pharma (BHVN) PT Raised to $19 at Morgan Stanley
August 12, 2026 8:11 AM - StreetInsider
Biohaven Pharma (BHVN) PT Raised to $23 at RBC Capital
August 11, 2026 7:57 AM - StreetInsider
Biohaven Pharma (BHVN) Misses Q2 EPS by 3c
August 10, 2026 4:24 PM - StreetInsider
Form 8-K Biohaven Ltd. For: Aug 10
August 10, 2026 4:23 PM - SEC Filing
Form 10-Q Biohaven Ltd. For: Jun 30
August 10, 2026 4:21 PM - SEC Filing
Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results
August 10, 2026 4:02 PM - PR NewsWire
Form 8-K Biohaven Ltd. For: Aug 03
August 7, 2026 4:12 PM - SEC Filing
Biohaven adds AI investor John Yetimoglu to its board
August 6, 2026 7:00 AM - StreetInsider
Biohaven Appoints Technology Investor John Yetimoglu to Board of Directors
August 6, 2026 7:00 AM - PR NewsWire
Jury awards Biohaven and Yale $4M in trade secret case
July 27, 2026 7:01 AM - StreetInsider
Federal Jury Finds Avilar Therapeutics and RA Capital Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Awards Biohaven and Yale University $4 Million
July 27, 2026 7:00 AM - PR NewsWire
Full Article List
